Efficacy of yoga and its probable mechanism of action on lifestyle-related chronic kidney disease: a randomized clinical trial
Annals of Behavioral Medicine · 2026
DOI: 10.1093/abm/kaaf101 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Behavioral Medicine, 2026. Verfasst von Rajesh G Nair und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Bioscience Lab, Anvesana Research Labs, S-VYASA [Deemed to be University], Bangalore 560105, India. Hauptthemen laut MEDLINE: Yoga, Renal Insufficiency, Chronic, Life Style. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Department of Science & Technology, India.
Abstract (Originalsprache)
Background
The rising incidence and debilitating impact of lifestyle-related chronic kidney disease (CKD) are alarming. Although yoga has shown favorable results in end-stage CKD, its efficacy in earlier stages remains unexamined.
Purpose
This study assesses the efficacy and evaluates the mechanism of action of yoga on early stages of CKD.
Methods
The study followed a 2-armed randomized controlled trial design. The study was conducted at Father Muller Medical College & Hospital, Mangalore, India from January 2022 to September 2022. CKD patients (stages 3 and 4) with diabetic or hypertensive etiology, aged 35-60, were randomly allocated to the intervention (41) and control group (40). The intervention group received yoga practices for 12 weeks (5 hours/week) in addition to usual care; the control group received only usual care. Primary outcome measures included kidney function parameters, blood pressure, oxidative stress markers, antioxidant markers, and transforming growth factor-β1 (TGF-β1).
Results
Among the CKD participants (mean [SD], age, 54 [5.3] years; 61 [85%] males), yoga group showed significant improvement compared to the Control in serum creatinine (mean difference −0.42 (95% CI, −0.74 to −0.09); P = .013), estimated glomerular filtration rate (6.94 (95% CI, 1.76 to 12.11); P = .030), urine albumin-to-creatinine ratio (−464.2 (95% CI, −880.3 to −48.01); P = .029), and TGF-β1 (−218.2 (95% CI, −401.9 to −34.3); P = .021), along with blood pressure, oxidative-stress, and antioxidant markers. Mediation analysis demonstrates that reduced TGF-β1 levels, acting as a mediator, significantly convey the beneficial effects of yoga.
Conclusion
The study shows the beneficial effects of 12-week yoga practice on anthropometric, biochemical, and molecular markers in patients with stages 3 and 4 CKD. These findings may encourage the integration of yoga as a potent adjunct therapy alongside usual care in the management of earlier stages of CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Bioscience Lab, Anvesana Research Labs, S-VYASA [Deemed to be University], Bangalore 560105, India.
- Anvesana Research Labs, S-VYASA [Deemed to be University], Bangalore 560105, India.
- Division of Yoga & Life Sciences, S-VYASA [Deemed to be University], Bangalore 560105, India.
- Department of Nephrology, Father Muller Medical College & Hospital, Mangalore 575004, India.
ORCID-Profile: Rajesh G Nair
Förderung
- Department of Science & Technology, India
Zitieren
APA
Nair, R. G., Mavathur, R., Manjunath, N. K., & Manjunath, J. (2026). Efficacy of yoga and its probable mechanism of action on lifestyle-related chronic kidney disease: a randomized clinical trial. Annals of Behavioral Medicine. https://doi.org/10.1093/abm/kaaf101
Vancouver
Nair RG, Mavathur R, Manjunath NK, Manjunath J. Efficacy of yoga and its probable mechanism of action on lifestyle-related chronic kidney disease: a randomized clinical trial. Annals of Behavioral Medicine. 2026. doi:10.1093/abm/kaaf101
BibTeX
@article{Nair2026,
author = {Nair, Rajesh G and Mavathur, Ramesh and Manjunath, N K and Manjunath, J},
title = {Efficacy of yoga and its probable mechanism of action on lifestyle-related chronic kidney disease: a randomized clinical trial},
journal = {Annals of Behavioral Medicine},
year = {2026},
doi = {10.1093/abm/kaaf101}
}
EUVIMED